|1.||Diagana, Thierry T: 2 articles (10/2014 - 09/2010)|
|2.||Kumar, Sushil: 1 article (05/2015)|
|3.||Kumari, Renu: 1 article (05/2015)|
|4.||Pandey, Richa: 1 article (05/2015)|
|5.||Ghani, A C: 1 article (01/2015)|
|6.||Leroy, D: 1 article (01/2015)|
|7.||Brock, P M: 1 article (01/2015)|
|8.||Churcher, T S: 1 article (01/2015)|
|9.||Upton, L M: 1 article (01/2015)|
|10.||Delves, M J: 1 article (01/2015)|
10/01/2014 - "This first-in-human randomized, double-blind, placebo-controlled, ascending-single and -multiple oral dose study was designed to evaluate the safety, tolerability, and pharmacokinetics in healthy volunteers of KAE609 (cipargamin; formerly NITD609), a spiroindolone now in trials for malaria treatment. "
09/03/2010 - "The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model."
05/01/2015 - "Among these, NITD609, ELQ300, decoquinate, usnic acid, torin-2 and NMT inhibitors not only cure simple malaria and are prophylactic against simple malaria, but they also cure relapsing malaria."
05/01/2015 - "Some of the putative next-generation antimalarials that possess in their scaffold structure several of the desired properties of malaria cure and control are exemplified by OZ439, NITD609, ELQ300 and tafenoquine that are already undergoing clinical trials, and decoquinate, usnic acid, torin-2, ferroquine, WEHI-916, MMV396749 and benzothiophene-type N-myristoyltransferase (NMT) inhibitors, which are candidates for future clinical usage. "
|2.||Body Weight (Weight, Body)
01/01/2015 - "Both primaquine (>6 mg/kg of body weight) and NITD609 (8.1 mg/kg) have significant impacts across multiple transmission settings, but artemether and lumefantrine (57 and 11.8 mg/kg), OZ439 (6.5 mg/kg), and primaquine (<1.25 mg/kg) demonstrated potent efficacy only at lower-transmission settings. "
|2.||Antimalarials (Antimalarial Agents)